<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37653777</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>34</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Efficacy of belimumab for severe childhood-onset systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A case report.</ArticleTitle><Pagination><StartPage>e34800</StartPage><MedlinePgn>e34800</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e34800</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000034800</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Therapy of childhood-onset systemic lupus erythematosus (cSLE) with drugs is unsatisfactory. Some new drugs such as belimumab and rituximab may improve the course of severe cSLE, although there are few reports on treatment efficiency for these new drugs, especially belimumab.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">Here we report on a 16-year-old girl who was diagnosed with cSLE at the age of 13. After several immunosuppressive treatments, which included high-dose steroids, hydroxychloroquine sulfate, cyclophosphamide, etc for blood system damage, she showed little clinical improvement and developed severe pericarditis. Induction treatment with a combination of intravenous high-dose steroids, methylprednisolone, and cyclophosphamide was started, but, after 55 days, the patient developed lupus encephalopathy, lung infection, and lupus nephritis. After using high-dose steroids, cyclophosphamide, plasma exchange, gamma globulin, and appropriate anti-pulmonary inflammation drugs, treatment with tacrolimus was attempted but poorly tolerated by the patient and withdrawn. Eventually, in December 2019, belimumab was initiated on an off-label basis as a last resource to treat lupus nephritis. Belimumab was well tolerated by the patient and resulted in a rapid and marked improvement in clinical symptoms and reduction in proteinuria, serum complement levels and anti-double strand DNA antibodies titer; of note, the patient developed no infectious complications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with belimumab could result in prompt remission of severe cSLE with multiple organ damage without the pulmonary infection side effects for children deemed intolerant to conventional and second-line induction therapies. Belimumab should be considered as a potentially efficacious treatment in patients in severe childhood-onset systemic lupus erythematosus.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, People's Hospital of Guizhou Province, Guiyang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nephrology, People's Hospital of Guizhou Province, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zha</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, People's Hospital of Guizhou Province, Guiyang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005921" MajorTopicYN="Y">Glomerulonephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37653777</ArticleId><ArticleId IdType="pmc">PMC10470770</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000034800</ArticleId><ArticleId IdType="pii">00005792-202308250-00049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li XY. Progress in the diagnosis and treatment for systemic lupus erythematosus in children. Dermatol Bull. 2018;35:335&#x2013;43.</Citation></Reference><Reference><Citation>KDIGO. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2012;2(Suppl 2):139&#x2013;224.</Citation></Reference><Reference><Citation>Bertsias GK, Tektonidou M, Amoura Z, et al. . Joint European league against rheumatism and European Renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465859</ArticleId><ArticleId IdType="pubmed">22851469</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27:2929&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042683</ArticleId><ArticleId IdType="pubmed">27283496</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana F, Alfano G, Leonelli M, et al. . Efficacy of belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report. BMC Nephrol. 2018;19:276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6196012</ArticleId><ArticleId IdType="pubmed">30342482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;wall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus. 2017;26:1333&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28162031</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#xe1;gati VD, Schwartz MM, et al. . The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman M, Hui-Yuen JS, et al. . Management of pediatric systemic lupus erythematosus: focus on belimumab. Drug Des Devel Ther. 2020;14:2504&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323799</ArticleId><ArticleId IdType="pubmed">32612353</ArticleId></ArticleIdList></Reference><Reference><Citation>Niaudet P. Treatment of lupus nephritis in children. Pract Ped Nephrol. 2000;14:0158&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">10684369</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadio JV, Jr, Holley KE, Ferguson RH, et al. . Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978;299:1151&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">309095</ArticleId></ArticleIdList></Reference><Reference><Citation>Derk CT, DeHoratius RJ. Systemic lupus erythematosus and acute pancreatitis: a case series. Clin Rheumatol. 2004;23:147&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15045630</ArticleId></ArticleIdList></Reference><Reference><Citation>Breuer GS, Baer A, Dahan D, et al. . Lupus-associated pancreatitis. Autoimmun Rev. 2006;5:314&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782555</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesher G, Breuer GS, Temprano K, et al. . Lupus-associated pancreatitis. Semin Arthritis Rheum. 2006;35:260&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M, Iaccarino L, Zen M, et al. . When to use belimumab in SLE. Expert Rev Clin Immunol. 2017;13:737&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28463023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui-Yuen JS, Nguyen SC, Askanase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. Lupus. 2016;25:1086&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">27497253</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vollenhoven RF, Petri MA, Cervera R, et al. . Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396451</ArticleId><ArticleId IdType="pubmed">22337213</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzman RM, Gallacher AE, et al. . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>